Internal Medicine, Rheumatology · Aventura, FL
NPI
1255440384
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2801 NE 213th St Ste 801
Aventura, FL, 33180
Phone (305) 652-6676
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.1M
385,140 services
Medicare patients, 2024
947
Average age 76
Drug cost, 2024
$2.7M
2,500 prescriptions
Company payments, 2025
$24K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Norman B Gaylis was code J3111 (injection, romosozumab-aqqg, 1 mg), 110,479 times for 113 patients. In total Norman B Gaylis billed 385,140 services in 108 codes, and Medicare paid $4.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 110,479 | 113 | $8.50 | $939K |
| J3262 Injection, tocilizumab, 1 mg | Office | 85,672 | 32 | $4.71 | $403K |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 43,200 | 17 | $3.61 | $156K |
| J0897 Injection, denosumab, 1 mg | Office | 30,482 | 324 | $20.46 | $624K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 14,400 | 20 | $9.06 | $130K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 11,900 | 43 | $24.96 | $297K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 9,258 | 50 | $0.23 | $2,091 |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 9,019 | 159 | $0.10 | $934 |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 5,371 | 22 | $16.07 | $86K |
| 96401 Chemotherapy Administration | Office | 1,397 | 280 | $54.88 | $77K |
| 99214 Office E&M - Established | Office | 1,165 | 576 | $101.44 | $118K |
| 96413 Chemotherapy Administration | Office | 746 | 144 | $99.46 | $74K |
| 96415 Chemotherapy Administration | Office | 571 | 88 | $21.74 | $12K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 497 | 190 | $0.09 | $44.73 |
| 99213 Office E&M - Established | Office | 494 | 339 | $67.90 | $34K |
By year: 2022 $3.6M for 276,985 services; 2023 $3.5M for 256,556 services; 2024 $4.1M for 385,140 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87811 Immunoassay | 70 | 28 | $40.55 | $2,839 |
Medicare prescription drug claims, 2024
In 2024, the drug Norman B Gaylis prescribed most often to Medicare patients was Diclofenac Sodium, with 435 prescriptions and refills. In total Norman B Gaylis wrote 2,500 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Diclofenac Sodium Generic | 435 | 507 | 184 | $7,317 |
| Prednisone Generic | 302 | 465 | 113 | $1,709 |
| Methotrexate Methotrexate Sodium | 284 | 664 | 108 | $7,186 |
| Prolia Denosumab | 132 | 792 | 89 | $227K |
| Meloxicam Generic | 129 | 210 | 54 | $622 |
| Hydroxychloroquine Sulfate Generic | 109 | 250 | 45 | $3,988 |
| Folic Acid Generic | 106 | 294 | 40 | $700 |
| Evenity (2 Syringes) Romosozumab-Aqqg | 98 | 98 | 22 | $239K |
| Celecoxib Generic | 84 | 134 | 35 | $1,494 |
| Allopurinol Generic | 73 | 185 | 29 | $738 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 71 | 187 | 27 | $857 |
| Tramadol Hcl Generic | 52 | 52 | 27 | $246 |
| Remicade Infliximab | 52 | 56 | 11 | $307K |
| Gabapentin Generic | 33 | 47 | 12 | $329 |
| Enbrel Sureclick Etanercept | 31 | 31 | Under 11 | $243K |
Brand drugs: - claims; generic drugs: 1,930 claims; opioid claims: 53.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Norman B Gaylis $24K ($237 in general payments such as food, travel and fees and $24K for research) from 8 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $15K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.